Introduction

▼
In Germany, there are about 30 000 children and adolescents between 0 and 19 years of age with type 1 diabetes [1] . The aims of therapy are predominantly to avoid acute (e. g., hypoglycemia) and long-term complications (e. g., diabetic nephropathy) as well as to ensure normal physical, cognitive, emotional and social development [2] . To achieve these objectives, comprehensive and locally available facilities are needed, consistent with national and international evidence based guidelines [2, 3] . For Germany, studies indicate an improvement of outpatient medical care in patients with type 2 diabetes and improved metabolic control in children and adolescents with type 1 diabetes over the preceding years [4, 5] . Although the quality of medical care appears to be rather good for the whole of Germany, it is widely unknown whether there are regional disparities in diabetes care (including unequal accessibility to specialized care). Regional disparities in diabetes care have been reported for several countries. Studies from the US and Brazil demonstrated regional differences in the frequency of control exams (e. g., measurements of HbA 1C and blood lipids), or screening for diabetes related complications (e. g., retinopathy and nephropathy) [6, 7] . In Switzerland and Norway, regional differences have been observed with regard to HbA 1C , medical treatment and self-monitoring (e. g., sales of glucometer strips) [8, 9] . In Germany, regional variation in type 2 diabetes prevalence and treatment has been described [10, 11] .
However, there is a lack of studies investigating regional differences of medical care in pediatric patients with type 1 diabetes in Germany. The software "Diabetes-Patienten-Verlaufsdokumentation (DPV)" developed since 1995 in Ulm, Germany, has been used for continuous, longitudinal, prospective documentation of diabetes-related parameters [5] . Since DPV is applied nationwide, the health care of more than 90 % of all children and adolescents with type 1 diabetes in Germany is covered. Thus, the DPV database forms an appropriate basis for regional mapping. The objective of this study is to examine regional disparities in diabetes care in pediatric patients with type 1 diabetes at the level of federal states of Germany.
Patients and Methods
▼
Patients and data documentation
The present study is based on the DPV registry. DPV is currently used by 413 specialized diabetes care centers from Germany and Austria. Semi-annually, participating health care facilities transmit their locally documented data anonymized to Ulm, Germany, for central analysis and quality assurance [12] . In case of implausible or inconsistent data, centers are requested to correct data. Analysis of anonymized routine data within the German/Austrian DPV initiative was approved by the Ethics Committee of the Medical Faculty of the University of Ulm, Germany. This study is in accordance with the 1964 Helsinki declaration and its later amendments. As of March 2014, a total of 3 38 982 patients were documented in the DPV database. For the present analysis, pediatric patients (< 18 years of age) with type 1 diabetes from Germany were included. Patients without clear assignment to one of the 16 federal states of Germany (e. g., due to missing postcodes of residence) were excluded ( • ▶ Fig. 1 ). For each patient, clinical data of the years 2012 and 2013 were aggregated for this analysis.
Indicators of diabetic-related medical care
Indicators of outcome quality (HbA 1C -mathematically standardized to the reference range of 20-42 mmol/mol (DCCT: 4.05-6.05 %) by applying the multiple-of-the-mean (MOM) transformation method [5] , prevalence of overweight (> 90 th percentile, reference data: German Health Interview and Examination Survey for Children and Adolescents (KiGGS) [13] ), rates of severe hypoglycemia (requiring third-party assistance [14] )) and medical treatment (use of insulin pumps, use of rapid-acting insulin analogues, use of long-acting insulin analogues in patients on injection therapy) were analyzed.
Statistical analysis
Sociodemographic characteristics and clinical data were presented as mean with standard deviation (SD), as percentage or as events/patient-year (PY) for the whole study population.
Patients were assigned to the respective federal state corresponding to the postcodes of their current residence and data are presented stratified by the 16 federal states of Germany. For each variable, regional differences are illustrated in tertile-based chloropleth maps using traffic light scale for indicators of outcome quality and 3 different shades of blue for parameters reflecting medical treatment. Logistic regression models were created for the prevalence of overweight, use of insulin pump, use of rapid-and long-acting insulin analogues as outcome and federal state as predictor. Linear regression models were applied for HbA 1C as outcome. Events of severe hypoglycemia were analyzed by Poisson regression with time under risk as offset. Since substantial disparities in sociodemographic characteristics are present between the federal states [15] , all models were adjusted for sex, age groups (< 6 years, 6-< 12 years, 12-< 18 years), migratory background (children with at least one parent whose place of birth is outside of Germany), and diabetes duration in groups (< 2 years; ≥ 2 years), respectively. Statistical analysis was performed using SAS 9.4 (Statistical Analysis Software, SAS Institute, Cary, NC, USA); the limit of significance of 2-sided tests was set at p < 0.05.
Results
▼
The study sample comprised 24 928 pediatric patients with type 1 diabetes.
• ▶ Table 1 shows sociodemographic and clinical data of the total study population.
• ▶ 
Medical treatment
In children and adolescents living in Southern Germany and in Bremen, the use of insulin pumps was low (26.3-28.8 %). The highest pump use was among children and adolescents living in Schleswig-Holstein (51.8 %). Patients in Eastern Germany and Saarland most commonly used rapid-acting insulin analogues (87.9-96.2 %), the lowest use was observed in Bremen (56.6 %). The percentage of patients treated with long-acting insulin analogues was highest in children and adolescents living in Southwestern Germany and in some federal states of Northeastern Germany (73.2-96.9 %), and lowest in parts of Northern and Western Germany (41.9-57.6 %).
Discussion
▼
Our objective was to analyze whether there are regional disparities in medical treatment and outcome quality in children and adolescents with type 1 diabetes within Germany. Considerable differences in outcomes and therapy, even after adjustment for sociodemographic characteristics, were observed.
In our study population, prevalence of overweight differed significantly between the 16 federal states (10.0-15.3 %). Data of KiGGS do not report similar differences [16] . However, in KiGGS, prevalence of overweight was only compared between new and old federal states of Germany [16] . Frequency of overweight in German children starting school stratified by the 16 federal states ranged between 8.4 % (Saxony) and 11.9 % (Bremen, Thuringia) [17] . Similar to our results, prevalence was lowest in Southeastern Germany (Bavaria, Brandenburg, Saxony, 8.4-8.6 %), whereas Bremen, Hamburg and Saxony-Anhalt were among the federal states with high prevalences (11.2-11.9 %) [17] . [20] . Studies also indicate a higher risk of hypoglycemic events [21] and a higher prevalence of overweight in children and adolescents with a low SES [17] . A low educational standard might be associated with low health literacy. This in turn can result in less benefit from diabetes education caused by a worse understanding of health care instructions. Results of the Program for International Student Assessment (PISA) can be used as an indicator for the level of education for adolescents at state level. PISA is an international assessment measuring reading, mathematics, and science literacy of students. Within Germany, students living in Saxony performed best in each PISA category, whereas students living in Bremen performed worst [22, 23] . Results of PISA exemplified by mathematics are given in • ▶ Table 3 [22] . With respect to diabetes outcome quality, patients from Saxony were among the best, and patients from Bremen among the worst. Although there are some concordances, the ranking of federal states according to PISA items does not entirely comply with the ranking according to clinical outcomes. In addition to education level, differences in household income could contribute to the disparities found. In Germany, there are large income inequalities between new (Eastern Germany and Mecklenburg-Western Pomerania) and old federal states of Germany [24] . Average income in old federal states of Germany is higher compared to that in new federal states of Germany [24] . Differences in indicators of outcome quality do not completely match with income inequalities in the general population. Whereas HbA 1C is rather worse in the new federal states of Germany, the rate of severe hypoglycemia was lowest in most parts of Eastern Germany. Even in overweight prevalence, there is no clear accordance with income differences. Unfortunately, our DPV data do not provide complete data with regard to SES-parameters, especially the parameter "income" is not available. Hence, no further analysis is possible. Disparities could be also explained by regional deprivation (e. g., unemployment rate, disposable income, physician density). Differences in living conditions are related to different capabilities and participation opportunities and might therefore influence health outcomes [19, 25, 26] .
• ▶ Fig. 3 presents the distribution of regional deprivation at district level in Germany according to the German Index of Multiple Deprivation (GIMD). The GIMD is based on demographic, socioeconomic and environmentally relevant variables from official statistics [27] . The federal states of Eastern Germany (except for most parts of Brandenburg), Mecklenburg-Western Pomerania and Bremen appear to be most affected by regional deprivation while particularly Bavaria seems to be least affected. Although our results on outcome and process variables do not indicate a clear East-West gradient, the regional distribution of the GIMD is in some respects in line with our findings. Especially results on diabetes outcomes in patients from Bavaria and Bremen are in concordance with the extent of regional deprivation. Another contributing factor might be the German federal system. Each federal state has its own Association of Statutory Health Insurance Physicians (North Rhine-Westphalia has 2 independent associations: North Rhine and Westphalia-Lippe). Their main task is to guarantee appropriate and comprehensively distributed health care. Therefore, a needs-based planning system was developed that regulates the allocation of physicians in 412 districts [28] . Studies indicated an unequal regional distribution of outpatient health care providers. Especially rural districts and deprived areas seem to be underserved [28] . Since these studies did not provide data of health care provision by diabetologists, it is not possible to draw conclusions about the occurrence of regional disparities in diabetes outcome quality. As one indicator for structural quality in medical care, travel distances between patient's residence and their diabetologists can be applied. A previous DPV-study revealed an association between long travel distances to patients' treatment center and a higher frequency in hospitalization as well as an increased number of hospital days [29] . In our study population, the least average distance was present for patients of the city-states Hamburg, Bremen and Berlin (9. respectively), the lowest number in Saarland and Bremen (56.0 and 57.8 patients/center, respectively). However, the actual number of diabetologists providing patient care is not available, hence, no statement with respect to the density of diabetes care can be made. Participation in disease management programs (DMP) differed between the federal states. Since 2004, DMPs have been established for patients with type 1 diabetes in Germany. They were originated to organize continuous and coordinated evidencebased medical care to improve patients' glycemic control and to reduce diabetes-related complications. According to DPV data, 37.4 % of the whole study population took part in DMPs. Patients in Hamburg most frequently participated in DMPs (80.6 %), whereas patients in Saxony-Anhalt attended rarely (3.7 %). DMP participation in Saxony (federal state with the best outcome quality) (30.4 %) was similar to that in Bremen (federal state with less favorable outcome quality) (28.1 %), but higher than participation in Saxony-Anhalt (less favorable outcome quality) (30.4 vs. 3.7 %) ( • ▶ Table 3 ). Hence, it can be speculated that participation in DMPs partially contributes to our findings. Disparities in outcomes and treatment might also be explained by patient's health insurance. In Germany, there are over 100 statutory health insurances with different additional services and benefits to the insurants. Furthermore, there are about 40 private health insurances. 86.6 % of the population is insured in statutory, 11.1 % in private health insurances. The distribution of health insurances differs within Germany. In old federal states of Germany, there are more people enrolled in statutory health insurances with high reputation and in private health insurances compared to people in new federal states of Germany [31] . It is assumed, that patients enrolled in private health insurances receive more expensive and more comprehensive medical care compared to patients enrolled in statutory health insurances [32] . A systematic review addresses advantages with respect to prescription of newer, innovative drugs, reduced waiting times and better communication with physicians [32] . In this context, it has to be taken into account that people enrolled in private health insurances tend to have a higher SES compared to people enrolled in statutory health insurances and this, as mentioned above, might also explain disparity. Regarding the supply of insulins, a study observed a more frequent use of insulin analogues in patients enrolled in private health insurances compared to patients enrolled in statutory health insurances (56.0 vs. 33.1 %) [33] . In our study, the use of rapid-acting insulin analogues ranged from 56. Table 3 ) [34] . There is some consistency with respect to the relatively high use of insulin pumps among patients from Hesse (39.2 %). However, in patients from Bavaria and Baden-Würt-temberg, the use of insulin pumps was rather low (27.3, 28.8 %). By far, the highest use was present among children and adolescents from Schleswig-Holstein (51.8 %). Potentially, this may be attributable to great efforts/special campaigns by local physicians [35] . Beside the German Diabetes Association, there are 15 regional diabetes associations (one per federal state, Bremen and Lower Saxony have a joint association) [36] . Hence, differences in medical treatment could be also a result of different local recommendations and guidelines as e. g., from Saxony [37] . Furthermore, positive experiences or preferences of physicians or patients in the federal states of Germany could have contributed to the disparities found. A strength of this study is its large number of pediatric patients from all over Germany. The database provides detailed information on patients' characteristics that allow to control for potential confounders. However, a limitation is that complete data on individual socioeconomic status (e. g., income), on structural characteristics (e. g., physician density) as well as information on patient's health insurance were not available. Moreover, lifestyle factors as physical activity or nutritional behavior were not recorded. Especially with respect to outcome quality, these factors might have affected our data. A further limitation is that only children and adolescents from participating DPV centers are integrated in this analysis. Although it can be assumed that > 90 % of pediatric patients with type 1 diabetes from Germany are covered in DPV, a selection bias cannot be excluded completely. Overall, due to the multicenter data collection, variability in the measurements cannot be completely eliminated, even though procedures are standardized by guidelines.
Conclusion
▼
Regional disparities in medical care for pediatric patients with type 1 diabetes were observed between the federal states of Germany. Selected quality indicators suggest that patients from Saxony have best outcomes. Considerable differences in the use of insulin pumps as well as the use of rapid-and long-acting insulin analogues were also present. Several factors as individual socioeconomic status, regional deprivation, type of health insurance or differences in reimbursement decisions might have contributed to the patterns observed.
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